Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference15 articles.
1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002
2. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007
3. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009
4. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease;Hibi;J Gastroenterol,2014
5. Comparative effectiveness of infliximab and adalimumab for Crohn's disease;Osterman;Clin Gastroenterol Hepatol,2014
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn’s Disease: Is There Any Difference between Small Intestine and Colonic Lesions?;Crohn's & Colitis 360;2023-05-23
2. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis;World Journal of Clinical Cases;2022-06-26
3. Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics;Journal of Gastroenterology and Hepatology;2019-02-06
4. Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta‐analysis;Journal of Digestive Diseases;2019-02
5. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease;Biologics: Targets and Therapy;2018-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3